Status:
COMPLETED
Skin Transcriptional Profiles In Psoriatic Patients Under Adalimumab Biotherapy
Lead Sponsor:
Poitiers University Hospital
Conditions:
Chronic Plaque Psoriasis
Eligibility:
All Genders
18-99 years
Phase:
PHASE2
Brief Summary
The expertise in the characterization of transcriptomics profile in lesional psoriatic skin and on the availability of innovative therapy for these patients.The investigators propose to follow the mod...
Eligibility Criteria
Inclusion
- Patients with chronic plaque psoriasis involving at least 10% of body surface area with no previous biotherapy.
- Adalimumab prescribed in usual practice
Exclusion
- Patients presenting a contraindication to the use of Adalimumab:
- hypersensibility in Adalimumab or in one of the excipients.
- Patients presenting an evolutionary tuberculosis or the other severe infections such as sepsis and opportunist infections
- presenting patients one cardiac insufficiencies moderated in severe
- Patients under anakinra or abatacept
- current participation in another study of clinical research
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT01872546
Last Update
October 11 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Poitiers
Poitiers, France, 86021